A systematic review and meta-analysis examined six molecular studies and 18 risk-based studies (that investigated risk of prostate cancer) regarding MMR gene mutations that found that 73% of PCa in mutation carriers were MMR deficient, estimating that carriers have a 3.67-fold increased risk of PCa [38]. Here, MRC1 is linked to prostate cancer.